肾康栓联合贝那普利治疗糖尿病肾病的临床研究

目的探讨肾康栓联合盐酸贝那普利片治疗糖尿病肾病的临床疗效。方法选取2018年4月—2020年3月天津中医药大学第一附属医院收治的86例糖尿病肾病患者为研究对象,根据随机数字表法将所有患者分为对照组和治疗组,每组各43例。对照组口服盐酸贝那普利片,10 mg/次,1次/d。治疗组在对照组治疗的基础上给予肾康栓,每日早中晚各1粒,睡前2粒。两组在治疗8周后统计疗效。观察两组的临床疗效,比较两组肾功能指标[白蛋白排泄率(UAER)、尿微量白蛋白、血清胱抑素C(Cys-C)]和细胞因子[内皮素-1(ET-1)、单核细胞趋化因子-1(MCP-1)、降钙素基因相关肽(CGRP)]水平。结果治疗后,治疗组的总有效率(93.02%)高于对照组(79.07%),差异有统计学意义(P0.05)。治疗后,两组的UAER、尿微量白蛋白、Cys-C水平均显著低于治疗前(P0.05);治疗后,治疗组的UAER、尿微量白蛋白、Cys-C水平比对照组低(P0.05)。治疗后,两组的ET-1、MCP-1水平显著降低,CGRP水平显著升高(P0.05);治疗后,治疗组患者的ET-1、MCP-1水平比对照组低,CGRP水平比对照组高(P0.05)。结论肾康栓联合盐酸贝那普利片治疗糖尿病肾病的疗效确切,可改善肾功能,调节血清细胞因子水平,安全性良好,具有良好的临床价值。

Clinical study on Shenkang Suppository combined with benazepril in treatment of diabetic nephropathy

Objective To investigate the clinical effect of Shenkang Suppository combined with Benazepril Hydrochloride Tablets in treatment of diabetic nephropathy. Methods Patients (86 cases) with diabetic nephropathy in the First Teaching Hospital of Tianjin University of TCM from April 2018 to March 2020 were randomly divided into control and treatment groups, and each group had 43 cases. Patients in the control group were po administered with Benazepril Hydrochloride Tablets, 10 mg/time, once daily. Patients in the treatment group were given Shenkang Suppository on the basis of the control group, 1 grain in the morning, noon and evening, 2 grains before bed. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and renal function indexes (UAER, urinary microalbumin, and Cys-C) and cytokines (ET-1, MCP-1, and CGRP) in two groups were compared. Results The total effective rate of the treatment group was higher than that of the control group, and the difference was statistically significant (P<0.05). The levels of UAER, urinary microalbumin, and Cys-C in the two groups were significantly lower than those before treatment (P<0.05). After treatment, UAER, urinary microalbumin, and Cys-C in the treatment group were lower than those in the control group, the difference was statistically significant (P<0.05). After treatment, the levels of ET-1 and MCP-1 were significantly decreased, but the levels of CGRP were significantly increased (P<0.05). After treatment, the levels of ET-1 and MCP-1 in the treatment group were lower than those in the control group, but the levels of CGRP in the treatment group was higher than that in the control group, the difference was statistically significant (P<0.05). Conclusion Shenkang Suppository combined with Benazepril Hydrochloride Tablets has clinical curative effect in treatment of diabetic nephropathy, can improve renal function, regulate the level of serum cytokines, with good safety, which has good clinical value.